Ensemble Therapeutics announced the initiation of a drug discovery collaboration with a subsidiary of Alexion Pharmaceuticals which is focusing on developing and commercializing life-transforming therapies for patients with life-threatening, ultra-rare disorders. The collaboration will deploy Ensemble’s proprietary drug discovery platforms for several undisclosed drug targets identified by Alexion to create highly innovative small molecule therapeutic candidates. Under the terms of the collaboration, Ensemble will screen its Ensemblin collection of more than 10M macrocycles against several disease drug targets specified by Alexion, utilizing Ensemble’s extensive medicinal chemistry capabilities to discover new small molecule clinical candidates. Alexion will have the exclusive worldwide rights to develop and commercialize candidates arising from the collaboration. Other terms of the agreement were not disclosed. Ensemble will receive an upfront payment and research support, and can earn additional payments upon the achievement of certain development and commercial milestones.